TYK Medicines, Inc
2410.HK
Hong Kong Stock Exchange7.26
HKD
+0.10
- -
TYK Medicines, Inc
2410.HK
(Hong Kong Stock Exchange)
Recent
price
7.26
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TYK Medicines TYK Medicines, Inc. (2410.HK), a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of small molecule oncology drugs targeting solid tumors. The company develops a pipeline of innovative product candidates including TY-9591, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR mutations including brain metastases and L858R mutations; TY-302, an oral CDK4/6 inhibitor for breast cancer, prostate cancer, and other advanced solid tumors; TY-2136b, an oral ROS1/NTRK inhibitor for solid tumors; TY-2699a, a selective CDK7 inhibitor for advanced and metastatic solid tumors; TY-0540, a selective CDK2/4/6 inhibitor for advanced solid tumors; TY-1054, an oral YAP/TEAD inhibitor for cancer treatment; TY-1210, a selective CDK2 inhibitor for solid tumors; TY-0609, a selective CDK4 inhibitor for cancer; TY-3200, an EGFR degrader; and additional candidates targeting RET fusions, EGFR exon 20 insertions, HER2 exon20 insertions, and PI3Kα allosteric inhibition. Founded in November 2017 and headquartered in Huzhou, Zhejiang Province, China, with administrative headquarters in Shanghai and R&D facilities in Zhengzhou, Henan Province, TYK Medicines operates primarily in China while advancing its programs toward global markets through a fully integrated chain from drug discovery to manufacturing, including ongoing construction of drug product plants in Changxing and Shanghai's Songjiang District. Recent developments include the completion of a placing of new H shares under general mandate on July 28, 2025, to fund acquisitions, investments, in-licensing, and collaborations such as potential combination therapies for TY-9591 and partnerships with universities or institutions; advancements in TY-9591 demonstrating superiority over osimertinib in pivotal trials for EGFR-mutant NSCLC brain metastases, positioning it for imminent market approval; and presentations at conferences in 2025 on candidates like TY-2699a, TY-4028 for EGFR/HER2 exon20 mutations, and TY-1781/12 CDK2 inhibitors.